Analysts Set Expectations for Aurora Cannabis Q2 Earnings

Key Points

• Analysts have revised their Q2 2026 earnings per share estimate for Aurora Cannabis down to ($0.10) from the previous ($0.08), indicating continued challenges for the company.
• Aurora Cannabis shares have risen 6.7%, opening at C$6.17, despite having a negative price-to-earnings ratio of -7.62.
• Senior officer Andre Jerome recently purchased 8,000 shares at an average price of C$5.83, reflecting insider confidence in the company's future.

Aurora Cannabis Inc. (TSE:ACB - Free Report) - Atb Cap Markets decreased their Q2 2026 earnings per share estimates for Aurora Cannabis in a report released on Wednesday, August 6th. Atb Cap Markets analyst F. Gomes now expects that the company will post earnings of ($0.10) per share for the quarter, down from their previous estimate of ($0.08). The consensus estimate for Aurora Cannabis' current full-year earnings is ($0.22) per share. Atb Cap Markets also issued estimates for Aurora Cannabis' Q3 2026 earnings at ($0.05) EPS, Q4 2026 earnings at ($0.02) EPS, FY2026 earnings at ($0.43) EPS, FY2027 earnings at ($0.09) EPS, FY2028 earnings at $0.21 EPS and FY2029 earnings at $0.41 EPS.

Aurora Cannabis Stock Up 6.7%

Shares of ACB opened at C$6.17 on Monday. The company has a debt-to-equity ratio of 18.72, a quick ratio of 2.48 and a current ratio of 3.42. The stock has a 50 day moving average price of C$6.54 and a 200 day moving average price of C$6.71. The stock has a market capitalization of C$337.55 million, a price-to-earnings ratio of -7.62 and a beta of 2.71. Aurora Cannabis has a one year low of C$4.95 and a one year high of C$9.90.

Insider Transactions at Aurora Cannabis

In related news, Senior Officer Andre Jerome bought 8,000 shares of the company's stock in a transaction on Friday, June 20th. The stock was bought at an average cost of C$5.83 per share, for a total transaction of C$46,640.00.

Aurora Cannabis Company Profile

Aurora Cannabis, headquartered in Edmonton, Canada, cultivates and sells medicinal and recreational cannabis through a portfolio of brands that includes Aurora, CanniMed, Daily Special, MedReleaf, and San Rafael '71. Although the company primarily operates in Canada, it has expanded internationally through medical cannabis exporting agreements or cultivation facilities in more than 20 countries.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.